Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial - Concepedia

Concepedia

Publication | Open Access

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial

DOI Full Paper Access

45

Citations

30

References

2017

Year

Émilie Cornec-Le Gall, Jaime D. Blais, María V. Irazabal, Olivier Devuyst, Ron T. Gansevoort, R. D. Perrone, Arlene B. Chapman, Frank S. Czerwiec, John Ouyang, Christina M. Heyer,

Nephrology Dialysis Transplantation

Abstract

This study confirms the prognostic value of the PROPKD score and suggests that it could reduce costs and enhance endpoint sensitivity by enriching future study populations for rapidly progressing ADPKD subjects.

References

	Year	Citations

Page 1